ritetronium

Subscribe to Selected New Research on ritetronium

19 relevant articles (0 outcomes, 1 trials/studies) found for this Bio-Agent

Description: RN given refers to parent cpd; structure

Also Known As:

Acolbifene; EM 652; EM-652; IEM 652; SCH 57068; SCH57068; bis(4-piperidinophenol)diimidonaphthalene-1,4,5,8-tetracarboxylic acid dibenzosulfoethylate; bis(p-piperidinophenol)diimidonaphthalene-1,4,5,8-tetracarboxylic acid dibenzosulfoethylate; ritebronii; ritebronium; ritetronium dibenzenesulfonate; ritetroniy; 1,1'-((1,3,6,8-tetrahydro-1,3,6,8-tetraoxobenzo(lmn)(3,8)phenanthroline-2,7-diyl)di-4,1-phenylene)bis(1-ethylpiperidinium),

Bio-Agent Context: Research Results

Heterocyclic Compounds: 23

1-Ring Heterocyclic Compounds

Piperidines: 7

ritetronium: 19

Experts

1.	Labrie, Fernand: 5 articles (10/2006 - 05/2002)
2.	Lemieux, Christian: 2 articles (05/2006 - 03/2003)
3.	Richard, Denis: 2 articles (05/2006 - 03/2003)
4.	Deshaies, Yves: 2 articles (05/2006 - 03/2003)
5.	Labrie, Claude: 2 articles (03/2004 - 05/2002)
6.	Candas, Bernard: 2 articles (03/2004 - 05/2002)
7.	Shah, Yatrik M: 1 article (11/2006)
8.	Al-Dhaheri, Mariam H: 1 article (11/2006)
9.	Basrur, Venkatesha: 1 article (11/2006)
10.	Rowan, Brian G: 1 article (11/2006)

Related Diseases

1.	Obesity 03/01/2003 - "DISCUSSION: EM-652 is an effective agent to prevent diet- and OVX-induced obesity and its associated cardiovascular risk factors such as insulin resistance" 03/01/2003 - "This study aimed to assess the ability of EM-652, alone or with dehydroepiandrosterone (DHEA), to prevent obesity and related metabolic abnormalities induced by an obesity-promoting diet and ovariectomy" 03/01/2003 - "The estrogen antagonist EM-652 and dehydroepiandrosterone prevent diet- and ovariectomy-induced obesity." Order ALL the reference details at left...
2.	Breast Neoplasms (Breast Cancer) 02/01/2005 - "As a pure antagonist of breast tumor development and growth, acolbifene does not stimulate endometrial tissue" 09/01/2004 - "Potentially, E(2) + SCH 57068 could be combined for the treatment and prevention of breast cancer or as a novel hormone replacement therapy." 02/01/2005 - "Acolbifene could also induce DNA damage in the S30 breast cancer cell line" 05/10/2002 - "Our present findings indicate that EM-652, in addition to being the most potent antiestrogen on human breast tumor growth, has no agonistic effect in breast and endometrial tissues" 12/01/2001 - "EM-652 is the most potent antiestrogen to inhibit the growth of human breast cancer ZR-75-1, MCF-7 and T-47D cells in vitro" Order ALL the reference details at left...
3.	Neoplasms (Cancer) 04/01/1999 - "EM-652 was also the most potent inhibitor of the percentage of cycling cancer cells" 10/01/2003 - "Most importantly, 93% of the tumors which had become undetectable under EM-652 treatment did not reappear when exposed to estrogen challenge for 12 weeks, thus achieving an overall 61% cure rate" 10/01/2003 - "RESULTS: EM-652 not only prevented estrogen-induced tumor growth but it reduced tumor size to 20% of the pretreatment value" 05/01/2006 - "Acolbifene (ACOL) is a fourth-generation selective estrogen receptor modulator (SERM) that has strong and pure antiestrogenic properties toward estrogen-sensitive cancers, but improves energy and lipid metabolism in an estrogen-like fashion in rodent models" 09/01/2005 - "The cancer-preventing selective estrogen receptor modulator (SERM) acolbifene (ACOL) exerts a potent and pure antiestrogenic action in the mammary gland and uterus, yet it displays beneficial, estrogen-like actions on energy and lipid metabolism in rodents" Order ALL the reference details at left...
4.	Uterine Neoplasms (Uterine Cancer) 03/01/2003 - "OBJECTIVE: EM-652 is a pure antiestrogen in human breast and uterine cancer cells that also reduces bone loss and plasma lipid levels in the rat" 05/10/2002 - "Since previous data have shown benefits of EM-652 on bone density and lipid profile, this compound could be an ideal candidate for chemoprevention of breast and uterine cancers, while protecting against osteoporosis and cardiovascular disease." 07/01/2001 - "The combination of DHEA with a fourth generation SERM, such as EM-652 (SCH 57068), a compound having pure and potent antiestrogenic activity in the mammary gland and endometrium, could provide major benefits for women at menopause (inhibition of bone loss and serum cholesterol levels) with the associated major advantages of preventing breast and uterine cancer" Order ALL the reference details at left...
5.	Endometrial Neoplasms (Endometrial Cancer) 12/01/2001 - "In order to minimize the risks of endometrial cancer and the development of resistance to antiestrogen therapy, we have synthesized the orally active antiestrogen EM-652 which is the most potent of the known antiestrogens and exerts pure antiestrogenic activity in the mammary gland and endometrium" 08/15/1997 - "Thus, as assessed by their activity in the human Ishikawa endometrial carcinoma cells, EM-800 and EM-652 are the most potent known antiestrogens in Ishikawa cells, and, most importantly, they are devoid of the estrogenic activity observed in these human endometrial cancer cells with (Z)-4-OH-tamoxifen, (Z)-4-OH-toremifene, droloxifene, and raloxifene." Order ALL the reference details at left...

Related Drugs and Biologics

1.	Dehydroepiandrosterone (DHEA)
2.	Estrogens (Estrogen)
3.	Estrogen Receptor Modulators (Antiestrogen)
4.	Selective Estrogen Receptor Modulators (SERM)
5.	EM 800
6.	Tamoxifen
7.	3-hydroxytamoxifen (droloxifene)
8.	ritetronium
9.	Raloxifene (Evista)
10.	Toremifene (Fareston)

Related Therapies and Procedures

1.	Ovariectomy (Oophorectomy)
2.	Hormone Replacement Therapy (Therapy, Hormone Replacement)
3.	Chemoprevention
4.	Heterologous Transplantation (Xenotransplantation)

Best Treatments:
Research Summary Report
on Obesity

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 781 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>